CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.2.2.1. Competitive intelligence of companies and their strategies
3.3. MARKET SHARE ANALYSIS, 2016
3.4. MARKET DYNAMICS
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.4.4. Impact analysis
3.5. CLINICAL TRIALS
CHAPTER 4 GLOBAL DIABETES THERAPEUTICS MARKET, BY PRODUCT
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. INJECTABLES
4.2.1. Insulin
4.2.1.1. Market size and forecast
4.2.2. Glucagon-like peptide-1 (GLP-1) receptor agonists
4.2.2.1. Market size and forecast
4.2.3. Amylinomimetic drug
4.2.3.1. Market size and forecast
4.2.4. Key market trends
4.2.5. Growth factors and opportunities
4.2.6. Market size and forecast
4.3. ORAL-ANTIDIABETIC DRUGS (OAD)
4.3.1. Biguanides
4.3.1.1. Market size and forecast
4.3.2. Sulfonylureas
4.3.2.1. Market size and forecast
4.3.3. Thiazolidinediones
4.3.3.1. Market size and forecast
4.3.4. Alpha-glucosidase inhibitors
4.3.4.1. Market size and forecast
4.3.5. Dipeptidyl Peptidase IV (DPP-4) inhibitors
4.3.5.1. Market size and forecast
4.3.6. Meglitinides
4.3.6.1. Market size and forecast
4.3.7. Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors
4.3.7.1. Market size and forecast
4.3.8. Key market trends
4.3.9. Growth factors and opportunities
4.3.10. Market size and forecast
CHAPTER 5 DIABETES THERAPEUTICS MARKET, BY REGION
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. NORTH AMERICA
5.2.1. Key market trends
5.2.2. Key growth factors and opportunities
5.2.3. Market size and forecast
5.2.4. U.S.
5.2.5. Canada
5.2.6. Mexico
5.3. EUROPE
5.3.1. Key market trends
5.3.2. Key growth factors and opportunities
5.3.3. Market size and forecast
5.3.4. Germany
5.3.5. France
5.3.6. UK
5.3.7. Italy
5.3.8. Spain
5.3.9. Rest of Europe
5.4. ASIA-PACIFIC
5.4.1. Key market trends
5.4.2. Key growth factors and opportunities
5.4.3. Market size and forecast
5.4.4. Japan
5.4.5. China
5.4.6. India
5.4.7. Australia
5.4.8. South Korea
5.4.9. Rest of Asia-Pacific
5.5. LAMEA
5.5.1. Key market trends
5.5.2. Key growth factors and opportunities
5.5.3. Market size and forecast
5.5.4. Brazil
5.5.5. South Africa
5.5.6. Saudi Arabia
5.5.7. Rest of LAMEA
CHAPTER 6 COMPANY PROFILES
6.1. ASTRAZENECA PLC
6.1.1. Company overview
6.1.2. Operating business segments
6.1.3. Business performance
6.1.4. Key strategic moves and developments
6.2. BOEHRINGER INGELHEIM GMBH
6.2.1. Company overview
6.2.2. Operating business segments
6.2.3. Business performance
6.2.4. Key strategic moves and developments
6.3. ELI LILLY AND COMPANY
6.3.1. Company overview
6.3.2. Operating business segments
6.3.3. Key strategic moves and developments
6.4. GLAXOSMITHKLINE PLC
6.4.1. Company overview
6.4.2. Operating business segments
6.4.3. Business performance
6.4.4. Key strategic moves and developments
6.5. JOHNSON & JOHNSON
6.5.1. Company overview
6.5.2. Operating business segments
6.5.3. Business performance
6.5.4. Key strategic moves and developments
6.6. MERCK & CO., INC.
6.6.1. Company overview
6.6.2. Operating business segments
6.6.3. Business performance
6.6.4. Key strategic moves and developments
6.7. NOVARTIS AG
6.7.1. Company overview
6.7.2. Operating business segments
6.7.3. Business performance
6.7.4. Key strategic moves and developments
6.8. NOVO NORDISK
6.8.1. Company overview
6.8.2. Operating business segments
6.8.3. Business performance
6.8.4. Key strategic moves and developments
6.9. SANOFI S.A.
6.9.1. Company overview
6.9.2. Operating business segments
6.9.3. Business performance
6.9.4. Key strategic moves and developments
6.10. TAKEDA PHARMACEUTICAL COMPANY LIMITED
6.10.1. Company overview
6.10.2. Operating business segments
6.10.3. Business performance
6.10.4. Key strategic moves and developments